The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
分析师的判决：四位专家眼中的Arcturus Therapeutics
In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有4位分析师公布了Arcturus Therapeutics（纳斯达克股票代码：ARCT）的评级，提出了从看涨到看跌的各种观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.25, a high estimate of $87.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 14.31% from the previous average price target of $55.33.
分析师分析的12个月目标股价提供了见解，平均目标股价为63.25美元，最高估计为87.00美元，低估值为48.00美元。当前的平均价格从之前的平均目标价55.33美元上涨了14.31％，这是一个积极的转变。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
An in-depth analysis of recent analyst...
对分析师近期行...
登录免费看全文
登录/注册